227 results about "Infectivity" patented technology

The utility model relates to the field of antigen detection kits, and discloses an infectious bovine rhinotracheitis virus antigen detection kit which comprises a box body, a roller is rotatably connected to the bottom side in the box body, a clamping groove is formed in the upper side of the roller, a clamping pin is connected to the clamping groove in a clamping mode, and a placing table is fixedly connected to the upper side of the clamping pin. A plurality of swab placing grooves, an extraction tube placing groove and a detection card placing groove are respectively formed in the upper side of the placing table, the plurality of swab placing grooves, the extraction tube placing groove and the detection card placing groove are distributed in a circumferential array, and sampling swabs are arranged on the inner sides of the plurality of swab placing grooves; according to the utility model, a plurality of groups of sampling swabs, sample extraction tubes and antigen detection cards which are distributed in a circumferential array manner are placed on the placement table, so that when sampling personnel go to cattle for sampling one by one, the sampling personnel can rotate to detection materials such as the next group of antigen detection cards and the like only by pressing down the push rod and switching the angle of the placement table, and the operation is convenient and the use is simple.

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.

The invention discloses a chicken infectious anemia subunit vaccine composition as well as a preparation method and application thereof. The vaccine composition contains a mixture of CIAV (Chicken Infectious Anemia Virus) VP1 and VP2 proteins, the mixture of the VP1 and VP2 proteins is prepared by performing in-vitro renaturation on VP1 inclusion body proteins by using a gradient dialysis method, adding pre-purified VP2 proteins in the dialysis process to promote the recovery of key conformation epitopes of the VP1 proteins, and then gradually removing a denaturing agent to obtain the VP1 and VP2 protein mixture. And refolding the VP1 protein to obtain the protein. The soluble VP2 protein is used as a molecular chaperone to recover the VP1 protein from the inclusion body. According to the VP2 protein assisted synergistic refolding strategy, the key conformation epitope of the VP1 protein is recovered by using the natural function of the VP2 protein. Subsequently, the immunogenicity and protective efficacy of the refolded VP1 and VP2 protein mixture are evaluated, and an economic and effective technical means is provided for preventing and controlling chicken infectious anemia.

The invention provides an infectious bronchitis virus subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering vaccines. According to the chicken infectious bronchitis virus mutant protein disclosed by the invention, the amino acid sequence of the mutant protein is shown as SEQ ID NO.5. According to the avian infectious bronchitis virus subunit vaccine containing the recombinant avian infectious bronchitis virus mutant protein Kozak-IgKsp-IBV-M41-S-core-6His as an effective component, the glycosylation level of the vaccine is relatively high, the expression level is relatively stable, the virus return risk of a live vaccine does not exist, the safety is high, large-scale industrial preparation can be achieved, and the vaccine has good application prospects. The cost is low.

The invention discloses a bacillus safensis strain and application thereof in aquaculture, and relates to the technical field of aquaculture disease prevention and control, the obtained bacillus safensis strain ZY-1 forms spores under a certain fermentation condition, can be prepared into powder for preservation, has a long shelf life, has the bacteriostatic activity retention rate of more than or equal to 85% after being stored in a dark place for 12 months at 4-25 DEG C, and has the antibacterial activity of more than or equal to 7.2%. The production, transportation and storage cost is saved, main bacteriostatic effect factors of the bacillus safensis ZY-1 strain exist in extracellular metabolites, the bacillus safensis ZY-1 strain is stable in performance and resistant to high temperature, acid and alkali, ultraviolet rays, protease and the like, and fermentation supernatant of the bacillus safensis ZY-1 strain can be directly applied or prepared into spray-dried powder and is suitable for various aquaculture application scenes such as pond splashing and feed mixing and feeding. The metabolite spray-dried powder has a remarkable killing effect on high-pathogenicity vibrios VpAHPND and VpTPD, the minimum inhibitory concentrations of metabolite spray-dried powder respectively reach 23.44-46.88 mu g / ml and 46.88-93.75 mu g / ml, and the metabolite spray-dried powder can be used for preventing and controlling prawn infectious hepatopancreas necrosis and prawn transparent larva diseases induced by the metabolite spray-dried powder and also has a certain killing function on pathogens of other aquatic animals.

The application discloses a kit for detecting equine infectious anemia virus antibody and belongs to the field of animal virus antibody detection. The kit comprises equine infectious anemia virus p26-gp90 recombinant protein, mouse IgG and goat anti-mouse IgG, and the equine infectious anemia virus p26-gp90 recombinant protein is composed of an amino acid sequence shown in SEQ ID NO. 1. The kit is used for detecting equine infectious anemia virus antibody, is convenient and fast, has high sensitivity, has no cross reaction with other pathogens, has high specificity, has great clinical significance and wide application prospect.

There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.

The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.

The application belongs to the technical field of biology and particularly relates to an ELISA kit for detecting chicken astrovirus type II antibodies and a preparation method. The Cell-ELISA experiment is carried out by using LMH cells infected with chicken astrovirus type II to detect the chicken astrovirus type II antibodies. The method has no cross reactivity with positive serum of Newcastle disease virus, avian influenza virus, chicken infectious anemia virus, avian leukosis virus, Marek's virus and chicken infectious bursal virus, which indicates that the method has good specificity. The Cell-ELISA method is used to detect the chicken serum sample to be detected by using whole virus infection, and is assembled into a kit for measuring chicken astrovirus antibodies in serum. The kit can be used for serological diagnosis of chicken astrovirus type II infection, monitoring of the level of antibodies, epidemiological investigation and the like, and provides a novel and effective detection means for prevention and treatment of chicken astrovirus type II.

The invention belongs to the technical field of prevention and control of infectious bovine rhinotracheitis, and particularly relates to an infectious bovine rhinotracheitis virus capable of being copied in HCT-8 cells and application of the infectious bovine rhinotracheitis virus. The invention provides an infectious bovine rhinotracheitis virus BoHV (23) strain, and the preservation number of the infectious bovine rhinotracheitis virus BoHV (23) strain is CGMCC No. The BoHV (23) strain can cause cows to have typical herpes symptoms and respiratory tract infection symptoms at the same time, and can be copied in human colon adenocarcinoma cells HCT-8. The infectious bovine rhinotracheitis virus BoHV (23) strain can be used for preparing vaccines, establishing virus infected animal models, evaluating vaccine protection effects and preparing drugs for virus treatment, and has a good application prospect in prevention and control of infectious bovine rhinotracheitis.

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

The present invention relates to the treatment of viral infections using photosensitizers in dairy cattle. The invention also relates to the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species. The invention is also directed to methods of controlling infectious agents on milking equipment for dairy cattle. The invention is further directed to milking processes including the treatment of viral infections and / or the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species and / or the methods for controlling infectious agents on milking equipment for dairy cattle.

The invention discloses a multilayer detachable three-dimensional freshwater fish temporary rearing bin which comprises a bin body and a plurality of detachable temporary rearing bins located in the bin body, the temporary rearing bins are slidably arranged in containing grooves formed in the bin body, and the temporary rearing bins located on the same column are vertically aligned at equal intervals to serve as an experimental group. And a communicating assembly movably penetrating through each temporary rearing bin is arranged in each experimental group correspondingly. According to the freshwater fish temporary rearing device, distinguishing, temporary rearing, observation and experimental operation of freshwater fish can be achieved, circulation can be achieved, the communicating assembly is matched, fishes are prevented from entering other temporary rearing bins at the communicating position, connectivity of all the temporary rearing bins is assisted to be slowed down, great help is provided for observation of experimental operation such as virus resistance, infectivity and virus tolerance of the freshwater fish, and the survival rate of the freshwater fish is increased. The method has scientific research value and daily use value.

The invention provides a method for pooling samples prior to a diagnostic screen for a non-infectious disease. The method includes pooling only a portion of the obtained samples and storing the other portion for later use. Pooling samples represents a more time and cost-effective way to perform diagnostic screening.

This invention relates to the field of bioengineering technology, specifically to a recombinant adenovirus displaying a large antigen fragment on its capsid surface, its construction method, and its applications. The HVR1 and HVR5 regions of the hexon hypervariable region of this virus are replaced by gene fragments containing exogenous genes; each exogenous gene fragment has a flexible linker attached to both ends, and the gene sequence of the flexible linker is shown in SEQ ID No. 1. By precisely locating the naturally variable HVR1 and HVR5 loop regions exposed on the surface of the hexon protein as insertion sites, and supplementing them with flexible linkers, the core problem of exogenous sequence insertion disrupting the stability of the hexon structure is successfully solved. This allows for stable packaging to produce viral particles with high titers and infectivity, enabling the development of a new generation of highly efficient and safe capsid-displaying adenovirus vaccines.

The invention belongs to the technical field of gene engineering, and particularly relates to a construction method and application of a recombinant vector based on bCoro1a gene 3 'UTR editing. The recombinant vector consists of an upstream homologous arm of a targeting site, 3 'UTR inserted into a target sequence, 200bp of a nucleotide tailing signal of bCoro1a, a selection marker and a downstream homologous arm of the targeting site; the targeting site is the 29 or 70 site of the 3 'UTR of the bCoro1a gene; the sequence of the 3 'UTR of the bCoro1a gene is as shown in SEQ ID NO. 48; the selection marker comprises enhanced green fluorescent protein and puromycin, the bCoro1a 3 'UTR edited gene expression regulation and control system is based on bCoro1a 3' UTR edited gene expression regulation and control system, and the expression level of bCoronin-1A is reduced in a targeted manner by inserting a specific bta-miR-27b target sequence into 3 'UTR, so that M.tb immune escape is inhibited, and the M.tb infection resistance of a host is improved.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

The application discloses a chicken Newcastle disease, avian influenza and chicken infectious rhinitis triple inactivated vaccine and preparation and application thereof, and relates to the technical field of bioengineering. The application discloses a preparation method and application of a chicken Newcastle disease, avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine. The preparation method comprises the following steps: constructing and expressing a serum B paracolon avian bacillus subunit protein expression strain; and preparing the chicken Newcastle disease, H9 subtype avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine at a certain ratio. The triple inactivated vaccine has good safety, can be used for the prevention of chicken Newcastle disease, H9 subtype avian influenza and A, B and C three serotypes paracolon avian bacillus diseases in a laying hen group, and does not cause the decrease of the laying rate after immunization. Meanwhile, the paracolon avian bacillus subunit protein can improve the antibody level of the Newcastle disease and the H9 avian influenza, and the protection of the vaccine on the A, B and C three serotypes paracolon avian bacillus can reach 100%.

The invention relates to an infectious bronchitis subunit vaccine based on a nano-skeleton technology. Specifically, the invention provides a fusion protein which sequentially comprises an infectious bronchitis virus S protein fragment or a mutant thereof, a connecting peptide and helicobacter pylori ferritin from an N terminal to a C terminal, wherein the infectious bronchitis virus S protein fragment is S1 protein, and the amino acid sequence of the S protein fragment is as shown in SEQ ID NO. 2; the mutant of the chicken infectious bronchitis virus S protein fragment is S1-2 protein or S1-3 protein, the amino acid sequence of the S1-2 protein is shown as SEQ ID NO.4, and the amino acid sequence of the S1-3 protein is shown as SEQ ID NO.5. The invention further discloses a preparation method of the chicken infectious bronchitis virus S protein fragment.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention discloses respiratory tract infectious virus prevention and treatment equipment which comprises an oral cavity part, a throat part and a chest part, the oral cavity part comprises a spherical infrared radiation shell, an electric heating layer is attached to the inner layer of the spherical infrared radiation shell, and a holding tube communicated with the interior of a spherical cavity is fixedly installed at the lower end of the spherical infrared radiation shell; the present invention provides a device for preventing and treating new coronal influenza, influenza A, pandemic influenza and recently found respiratory infectious viruses such as HMPV.

This invention discloses a strain of Acanthamoeba that inhibits the pathogen of Fusarium graminearum and its applications. Acanthamoeba (Acanthamoeba rhysodes NJAU-ZY1, deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC NO: C2025219, demonstrates in plate experiments, liquid co-culture experiments, and pot experiments that inoculation with the protozoan Acanthamoeba NJAU-ZY1 significantly inhibits the growth of Fusarium graminearum pathogen, reduces its infectivity in wheat, alleviates the inhibitory effect of Fusarium graminearum on wheat growth, reduces the risk of diseases caused by this pathogen, and thus increases wheat biomass. This provides a new strategy and resource for the biological control of Fusarium graminearum pathogen and the scientific cultivation of wheat, and has important application value for the safe production of food crops.

The invention discloses a method for visually detecting mandarin fish iridovirus and infectious spleen and kidney necrosis virus based on RPA-CRISPR Cas12a / Cas13a, and belongs to the technical field of biological diagnosis. According to the method, a CRISPR / Cas system is combined with RPA amplification, a fluorescent reporter and a test strip are used for naked eye observation, and the method combines the advantages of different isothermal amplification technologies, has the advantages of short detection time, high specificity, no cross reaction, high sensitivity and the like, realizes rapid and accurate diagnosis of the two pathogens, and has a good application prospect. Important technical support is provided for prevention and control of mandarin fish diseases.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The invention relates to a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination and a kit for an infectious bronchitis virus. The invention belongs to the field of biology, and discloses a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination for GI-13 / GI-19 / GVI-1 typing and general detection of an infectious bronchitis virus. Comprising a first primer probe combination for distinguishing an infectious bronchitis virus from other viruses, a second primer probe combination for identifying a GI-13 type infectious bronchitis virus, and a third primer probe combination for identifying a GI-19 type infectious bronchitis virus, and the fourth primer probe combination is used for identifying the GVI-1 type avian infectious bronchitis virus. The PCR primer probe combination is suitable for an RT-qPCR detection system, and can be used for effectively distinguishing GI-19, GI-13 and GVI-1 type IBV viruses; meanwhile, the invention further discloses a kit.

Disclosed are adeno-associated virus (AAV) capsid protein variants that have improved infectivity and transduction efficiency for target cells, and uses thereof. Specifically, the disclosure relates to AAV2 variant capsid proteins selected by directed evolution for gene delivery to retinal cells, recombinant AAV vectors comprising the same, and uses thereof as gene delivery vehicles to retinal cells.

The utility model provides a disposable sterile protective cover. The disposable sterile protective cover comprises a main body assembly and a fixing assembly, the main body assembly comprises a cover body, a flexible bottom edge is arranged at the bottom of the cover body, a supporting frame is arranged on the inner wall of the cover body, a pair of operation openings are formed in one end of the cover body, rubber gloves extending towards the interior of the cover body are arranged at the operation openings, an air inlet and an air outlet are further formed in the cover body, and one-way valves are arranged at the air inlet and the air outlet. A window is further formed in the cover body, a protective sticker is adhered to the window, and a connecting assembly aiming at an infusion tube is arranged on the cover body close to the window in a penetrating manner; the fixing assembly comprises a hard frame, the top of the hard frame is provided with a first bonding layer used for being bonded with the flexible bottom edge, and the bottom of the hard frame is provided with a second bonding layer used for being bonded with a sickbed. The disposable sterile protective cover provided by the utility model can effectively isolate an infectious patient and effectively prevent virus transmission, is also convenient for medical personnel to nurse the patient, and is ingenious in structural design and easy to operate and use.

This invention relates to the field of eDNA enrichment and detection, and discloses a highly efficient method for the enrichment and detection of infectious hematopoietic organ necrosis virus (IHNV) eDNA. The method includes the following steps: preparing and pretreating an IHNV virus sample to obtain a standardized raw solution; subsequently, using a tangential flow enrichment device to efficiently concentrate the IHNV virus particles in the raw solution, achieving the enrichment of viral eDNA; and constructing an RT-qPCR quantitative detection system. By plotting a standard curve and a sample amplification curve, the virus recovery rate is accurately calculated, enabling accurate evaluation of the efficiency of the entire enrichment process. This invention overcomes the shortcomings of traditional methods, such as small processing volume, low efficiency, and cumbersome operation, achieving the goal of efficient and stable recovery of viruses from large-volume water samples.